Research summary

MariTide (maridebart cafraglutide, formerly AMG 133) is an investigational antibody–peptide conjugate that blocks GIP receptors and activates GLP-1 receptors. In a 52-week Phase 2 trial in adults with obesity without diabetes, several MariTide dose groups showed greater average body-weight loss than placebo. [8] [9]

Summary revised November 1, 2026. This editorial update does not constitute a new literature review.

Update History ▾
October 23, 2026: The filing-plan line now uses Lilly's own wording: Lilly plans to submit retatrutide for US approval in Q1 2027.
October 22, 2026: Added a MariTide vs Ozempic and Wegovy (semaglutide) section with the STEP 1 trial and the current semaglutide labels, a release-date answer, a drug-class answer, a plain-language mechanism paragraph, the obesity-related conditions in the MARITIME programme and five new FAQs. Re-checked the main ClinicalTrials.gov records and Amgen’s press releases on October 22, 2026: still no MariTide Phase 3 results or regulatory filing. October 20, 2026: Added MARITIME-PEN (NCT07871409), a twelfth Phase 3 study first posted on October 13, 2026, to the MARITIME section and the Phase 3 trials table; updated the ClinicalTrials.gov count to 30 maridebart cafraglutide studies (12 Phase 3, 3 Phase 2, 15 Phase 1), checked October 20, 2026. October 13, 2026: Initial publication, built from a source-by-source check of the WHO INN lists, the Phase 1, Phase 2 and discovery papers, 29 ClinicalTrials.gov records, Drugs@FDA, DailyMed, the European Medicines Agency medicines table and Amgen and Lilly releases, each checked on October 12, 2026 and re-checked on October 13, 2026. Amgen had reported no MARITIME Phase 3 results as of that date. Research-use-only framing applied throughout in line with Remy editorial standards.
Compliance note: this page is a research review, not a treatment guide. It does not provide human-use dosing, therapeutic recommendations, or any clinical-use instructions, and should be read in the same non-therapeutic frame required across Remy's research content.

This profile is for researchers and readers following the obesity drug pipeline. It sets out what MariTide is, how it works, the published trial results, its side effects, the release-date question and how it compares with retatrutide, tirzepatide and semaglutide, with references for each figure. MariTide matters to that field because it blocks the GIP receptor that tirzepatide and retatrutide activate, and because its trials test treatment once a month or less often.[3][15][20][4]

What Is Maridebart Cafraglutide?

Maridebart cafraglutide, also known as MariTide and formerly AMG 133, is an investigational obesity drug developed by Amgen.[1][8] It is an injectable that Amgen is studying for treatment once a month or less often.[3][4] The World Health Organization proposed the nonproprietary name in 2022 and confirmed it in 2023. Its definition describes a human IgG1-kappa monoclonal antibody against the glucose-dependent insulinotropic polypeptide receptor (GIPR), made in Chinese hamster ovary (CHO) cells and conjugated to two identical glucagon-like peptide-1 (GLP-1) analogues.[2][12]

The two halves of the name match the two halves of the molecule. In WHO naming, the stem “-glutide” marks glucagon-like peptide (GLP) analogues, and “-bart” marks full-length antibodies with engineered changes in their constant regions. Read that way, “maridebart” is the antibody and “cafraglutide” is the GLP-1 analogue.[13][14] That makes MariTide unusual on a peptide research site: tirzepatide and retatrutide are single peptides, while most of MariTide’s mass is antibody.[15][16][3] It also blocks a receptor that those two drugs activate, a puzzle covered in GIP receptor agonist vs antagonist: the obesity paradox.

The early data on MariTide come mainly from two published trials. The Phase 1 results appeared in Nature Metabolism in 2024, and the Phase 2 results in the New England Journal of Medicine in 2025.[3][8] More data are expected from the MARITIME Phase 3 programme, whose two main trials have an estimated primary completion date of January 21, 2027.[36]

Evidence and context

Maridebart cafraglutide (MariTide, formerly AMG 133) is Amgen’s investigational antibody–peptide conjugate: an antibody that blocks the GIP receptor, carrying two GLP-1 analogue peptides that activate the GLP-1 receptor.[1][2][3] As of October 12, 2026, Amgen has reported no Phase 3 results: both main MARITIME weight trials are active, not recruiting, with no results posted and primary completion estimated for January 21, 2027.[4][5][6][7] In Phase 2, adults with obesity and without diabetes lost 12.3% to 16.2% of body weight at 52 weeks, against 2.5% on placebo (treatment-policy estimand).[8][9]

It is not approved by the FDA or the European Medicines Agency.[10][11] There is no MariTide release date yet, because Amgen has not announced a regulatory filing.[4][35] Remy Research does not sell it; this page reviews the published research and trial records only.

Maridebart Cafraglutide Structure

The WHO definition, the 2024 Phase 1 paper and the 2026 discovery paper describe the same parts:[2][3][17]

Part What it is Source
Antibody Human IgG1-kappa monoclonal antibody that binds and blocks GIPR WHO INN
Production Made in Chinese hamster ovary (CHO) cells WHO INN
Peptide arms Two identical GLP-1(7–35) analogues WHO INN, Phase 1 paper
Peptide changes Aib (alpha-aminoisobutyric acid) at position 8, tyrosine at 16, glutamate at 22 (GLP-1 numbering) WHO INN
Linker An 18-residue linker on each arm (glycine–serine repeats ending in lysine) WHO INN
Attachment Thioether bond to an engineered cysteine in the antibody Discovery paper
Average mass 153,514 Da Phase 1 paper

Each peptide arm, with its linker, is about 47 amino acids long. By the INN chain numbering, the antibody itself has about 1,328 amino acids: two heavy chains of 450 and two light chains of 214.[2][3] At about 153.5 kDa, the whole molecule is roughly 32 times heavier than tirzepatide, a single peptide of 4,813.53 Da.[3][15]

Amgen says its team tested more than 150 antibody–peptide conjugate variations before choosing this design.[18] The discovery paper describes the chemistry: a bromoacetamide group at the end of each linker reacts with the engineered cysteine thiols to form a stable thioether link.[17]

Is MariTide a GLP-1 or a Peptide?

Is it a GLP-1? Partly. MariTide carries two GLP-1 analogue peptides and activates the GLP-1 receptor. Amgen describes it as an antibody–peptide conjugate that “activates the glucagon-like peptide-1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR)”.[4][3] It is not a stand-alone GLP-1 peptide like semaglutide, though: most of the molecule is an antibody that blocks the GIP receptor.

Is it a peptide? Only in part. US regulations define a protein as an amino acid polymer of more than 40 amino acids.[19] Our explainer Is retatrutide a peptide or a biologic? shows how close retatrutide sits to that line. MariTide is nowhere near it: its antibody part, about 1,328 amino acids made in CHO cells, is a protein, and each of its two arms is a synthetic 29-residue GLP-1 analogue, a peptide, joined to the antibody by an 18-residue linker.[2][3] We found no Amgen or FDA statement on how a future US application for it would be classified.

What drug class is it? The maridebart cafraglutide drug class has no single agreed name yet. Its Phase 2 paper calls it a long-acting peptide–antibody conjugate that combines GLP-1 receptor agonism with GIP receptor antagonism.[8] Amgen calls it an antibody–peptide conjugate, and the discovery paper uses the term antibody–drug conjugate.[4][17]

Maridebart Cafraglutide Mechanism of Action

The MariTide mechanism of action works on two hormone pathways at once. GLP-1 and GIP are incretin hormones that help regulate body weight through their receptors.[3] Labels for semaglutide, an approved GLP-1 medication, say that it stimulates insulin release when blood sugar is high, and that GLP-1 regulates appetite and calorie intake.[37][38]

MariTide does two things at once. Its antibody binds the GIP receptor and blocks it, while its two peptide arms activate the GLP-1 receptor; the Phase 1 paper confirmed both activities in cell-based tests.[3] Tirzepatide and retatrutide take the opposite approach at the GIP receptor: both activate it.[15][20]

Why MariTide Blocks the GIP Pathway (GIPR Antagonism)

The case for blocking GIPR comes from human genetics. Genome-wide studies in Japanese, European and North American populations linked lower GIPR expression or function to a lower body-mass index.[3] Amgen says its deCODE genetics unit found a GIPR variant in which lower receptor activity went with lower weight.[18] In diet-induced obese mice, antibodies that block GIPR protected against weight gain, and obese monkeys given them lost weight; combining them with a GLP-1 receptor agonist increased weight loss in both.[21] In obese monkeys treated weekly with AMG 133 for six weeks, body weight fell 11% and 13% from baseline in the two treatment groups.[3]

Why both blocking and activating GIPR can lower weight is still debated. An Amgen study found that long-term GIPR activation desensitises the receptor in fat cells, mimicking functional blockade.[22] The Phase 1 authors note that the molecule is probably too large to cross the blood–brain barrier. They suggest it acts where GLP-1 and GIP receptors sit outside that barrier, such as the area postrema. That is their hypothesis, not a finding.[3] For the competing explanations, see the GIP agonist vs antagonist paradox and our GLP-1, GIP and glucagon mechanism guide.

Maridebart Cafraglutide Clinical Trials: Phase 1 and 2

Phase 1 (first in human). This randomised, placebo-controlled study in adults with obesity had a single-treatment part (49 participants at six dose levels or placebo) and a repeated-treatment part (26 participants in three cohorts treated every 4 weeks). Safety was the primary end point; weight was exploratory.[3] In the highest repeated-treatment cohort, body weight fell 14.5% by day 85, against a 1.5% gain on placebo, and it was still up to 11.2% below baseline 150 days after the last treatment.[3] Blood levels peaked 4 to 6 days after treatment, and the mean half-life was about 14 to 16 days for intact MariTide and 21 to 24 days for total drug.[3]

MariTide Weight Loss Results in the Phase 2 Trial

Phase 2 (NCT05669599). This 52-week, double-blind, placebo-controlled trial randomised 592 adults into two cohorts: 465 with obesity and no diabetes, and 127 with obesity and type 2 diabetes (T2D). Its arms were given every 4 or every 8 weeks.[8] The results were published in the New England Journal of Medicine in 2025, and Amgen reported them under two estimands.[8][9]

Cohort and estimand MariTide (range across arms) Placebo
Obesity: policy −12.3% to −16.2% body weight −2.5%
Obesity: efficacy −16.3% to −19.9% body weight −2.6%
With T2D: policy −8.4% to −12.3% body weight −1.7%
With T2D: efficacy −12.1% to −17.0% body weight −1.4%
HbA1c, T2D: policy −1.2 to −1.6 percentage points +0.1 points

“Policy” is the treatment-policy estimand, which Amgen calls its intention-to-treat analysis: it counts every participant regardless of whether they kept taking the drug, and treats missing data after stopping as similar to placebo. “Efficacy” estimates the effect as if participants had stayed on treatment for all 52 weeks. Amgen says the gap between the two was driven by early discontinuations and a conservatively defined treatment-policy estimand.[9] The abstract does not say which arm produced the top of each range.[8] Amgen also reports improvements in waist circumference, blood pressure, high-sensitivity C-reactive protein (hs-CRP) and some lipids, and says weight loss had not plateaued by week 52.[9]

Amgen’s first Phase 2 release, in November 2024, described these as improvements in cardiometabolic markers across the MariTide arms and named triglycerides among them.[25] In the diabetes cohort, HbA1c, a measure of long-term blood sugar, fell by 1.2 to 1.6 percentage points against a 0.1-point rise on placebo (treatment-policy estimand).[8]

After week 52. Participants who had lost at least 15% and were still on treatment could enter Part 2, a further 52 weeks studying continued treatment, stopping, and less frequent maintenance treatment.[9] In February 2026 Amgen said Part 2 is complete and that “the large majority” of participants kept their Part 1 weight loss for another 52 weeks on lower monthly or quarterly maintenance treatment. It also said a separate Phase 2 study in type 2 diabetes (NCT06660173, 409 participants) showed meaningful falls in HbA1c and weight at 24 weeks.[23][24] Amgen has published no numbers for either study.[23]

MARITIME Phase 3: Status in October 2026

Amgen announced the MARITIME Phase 3 programme in November 2024.[25] ClinicalTrials.gov lists 30 maridebart cafraglutide studies, all sponsored by Amgen: 12 Phase 3, 3 Phase 2 and 15 Phase 1 (checked October 20, 2026).[24] The newest, MARITIME-PEN (NCT07871409), was first posted on October 13, 2026. It is an open-label Phase 3 study of at-home use of an autoinjector in about 230 adults with obesity or overweight without type 2 diabetes, and was not yet recruiting.[24] The two main weight trials, MARITIME-1 (3,853 adults without type 2 diabetes) and MARITIME-2 (1,105 adults with type 2 diabetes), measure the percentage change in body weight at week 72 against placebo.[6][7]

No Phase 3 results have been reported. Amgen’s August 4, 2026 quarterly results release calls MARITIME-1 and MARITIME-2 “ongoing”, and its news releases since then contain no MariTide results. Both registry records show no posted results and an estimated primary completion date of January 21, 2027.[4][5][6][7] We found claims online of a MARITIME topline readout; neither Amgen nor the registry supports them.

Trial Population and end point Status (Oct 2026)
MARITIME-1 Obesity or overweight, no T2D; weight at week 72 vs placebo (NCT06858839) Active, not recruiting; est. Jan 2027
MARITIME-2 Obesity or overweight with T2D; weight at week 72 vs placebo (NCT06858878) Active, not recruiting; est. Jan 2027
MARITIME-3-J Obesity disease in Japan; weight at week 72 vs placebo (NCT06987695) Active, not recruiting; est. Apr 2027
MARITIME-OSA-1 Sleep apnea on positive airway pressure (PAP) therapy; apnea–hypopnea index (AHI) at week 52 vs placebo (NCT07225686) Active, not recruiting; est. Aug 2027
MARITIME-OSA-2 Sleep apnea not on PAP therapy; AHI at week 52 vs placebo (NCT07226765) Active, not recruiting; est. Aug 2027
MARITIME-HF Heart failure with preserved or mildly reduced ejection fraction and obesity; cardiovascular (CV) death or heart failure events (NCT07037459) Recruiting; est. Jun 2028
MARITIME-CV Atherosclerotic cardiovascular disease with obesity or overweight; major CV events (NCT07037433) Active, not recruiting; est. Jun 2028
MARITIME-SWITCH Switch from a GLP-1 receptor agonist to one of two MariTide schedules; weight at week 68 (NCT07575399) Recruiting; est. Jan 2028
MARITIME-1 ext. Extension: long-term follow-on for MARITIME-1 completers (NCT07684235) Recruiting; est. Dec 2027
MARITIME-2 ext. Extension: long-term follow-on for MARITIME-2 completers (NCT07684144) Recruiting; est. Dec 2027
MARITIME-T2D-3 Type 2 diabetes, open-label vs once-weekly semaglutide; HbA1c at week 68 (NCT07866066) Not yet recruiting; est. Sep 2028
MARITIME-PEN Obesity or overweight, no T2D; open-label single-arm at-home autoinjector use (NCT07871409) Not yet recruiting; est. Jun 2027

Recruitment status and dates were checked on November 2, 2026. MARITIME-CV was active, not recruiting in the registry update posted October 29, 2026. “Est.” is the estimated primary completion date in each ClinicalTrials.gov record, which sponsors can revise.[24] Amgen says data from Phase 2 and from a separate Phase 1 study of lower starting regimens informed the Phase 3 programme, and its extension and switch studies test monthly, every-8-week and quarterly schedules.[9][4] Amgen also plans three Phase 3 studies in type 2 diabetes in 2026. MARITIME-T2D-3 is the only one on ClinicalTrials.gov so far, and it is the programme’s only trial with an active comparator.[4][24] For the two sleep apnea trials in context, see obesity drugs and sleep apnea; for timing across the field, see the 2026 obesity drug pipeline timeline.

Amgen describes MARITIME as a Phase 3 programme in obesity and obesity-related conditions.[25] Beyond weight and type 2 diabetes, the MariTide clinical trials in Phase 3 evaluate three other obesity-related conditions. MARITIME-OSA-1 and MARITIME-OSA-2 enrol adults with obstructive sleep apnea, with or without positive airway pressure therapy, and measure the change in the apnea–hypopnea index at week 52. MARITIME-HF enrols patients with heart failure and obesity and counts cardiovascular deaths and heart failure events. MARITIME-CV enrols patients with atherosclerotic cardiovascular disease and overweight or obesity, and counts major cardiovascular events such as heart attack and ischaemic stroke.[36] These two outcome trials follow patients for up to about 35 months and test whether treatment lowers that risk, rather than measuring weight at a fixed week.[36]

Is Maridebart Cafraglutide FDA Approved?

No. As of October 12, 2026, Drugs@FDA and DailyMed hold no approval or label for maridebart cafraglutide, and the European Medicines Agency’s medicines table has no entry for it.[10][11] Amgen describes it as an investigational therapy and has not announced a regulatory filing.[1][4] For where it sits among other obesity drugs, see the 2026 obesity drug approval tracker.

MariTide Release Date: When Could It Be Available?

There is no MariTide release date yet. MariTide is an investigational medicine, and Amgen has not announced a regulatory filing, so it has no launch date and no price.[1][4] Amgen’s press releases up to October 20, 2026 include no MariTide Phase 3 results or filing news.[35] On October 22, 2026, both main Phase 3 trials, MARITIME-1 and MARITIME-2, were still active, not recruiting, with no results posted and an estimated primary completion date of January 21, 2027.[36] Phase 3 results, a filing and a regulatory review would all have to come first, so any launch date quoted online today is a guess.

Maridebart Cafraglutide Side Effects

What Phase 1 and Phase 2 have shown so far:

There are no Phase 3 safety data yet, and Amgen has described the longest follow-up, the second year of Phase 2, only in words.[6][23]

Maridebart Cafraglutide vs Retatrutide

Retatrutide, from Eli Lilly, is a single peptide that activates three receptors: GIP, GLP-1 and glucagon.[16][20] MariTide activates only the GLP-1 receptor and blocks the GIP receptor, so the two act in opposite directions at GIPR.[3] Retatrutide is given once weekly in its trials, while MariTide is designed for treatment once a month or less often.[20][8][4]

Feature MariTide Retatrutide
Developer Amgen Eli Lilly
Molecule Antibody–peptide conjugate, ~153.5 kDa Single peptide
GLP-1 receptor Activates Activates
GIP receptor Blocks Activates
Glucagon receptor Not targeted Activates
Interval in trials Every 4 weeks or less often Once weekly
Weight, ITT estimand −12.3% to −16.2% vs −2.5% (Phase 2, 52 wk) −25.0% vs −3.9% (TRIUMPH-1, 12 mg arm, 80 wk)
Weight, efficacy −16.3% to −19.9% vs −2.6% −28.3% vs −2.2%
With T2D, ITT −8.4% to −12.3% vs −1.7% (52 wk) −18.8% vs −5.1% (TRIUMPH-2, 12 mg arm, 80 wk)
Stage, Oct 2026 Phase 3 under way, no results; not approved Phase 3 reported; not approved

“ITT estimand” groups Amgen’s treatment-policy and Lilly’s treatment-regimen estimands, which both count results regardless of adherence. These are separate trials, not a head-to-head comparison; see the caveats below.[9][29]

The headline numbers come from different phases and lengths. In Lilly’s Phase 3 TRIUMPH-1 trial (2,339 adults without diabetes, 80 weeks), the 12 mg arm lost 25.0% against 3.9% on placebo (treatment-regimen estimand), or 28.3% against 2.2% on the efficacy estimand.[20][30] In retatrutide’s 48-week Phase 2 trial, the 12 mg arm lost 24.2% against 2.1% (efficacy estimand).[31] In type 2 diabetes, TRIUMPH-2 reported 18.8% for the 12 mg arm against 5.1% at 80 weeks (treatment-regimen), compared with 8.4% to 12.3% against 1.7% at 52 weeks in MariTide’s Phase 2 diabetes cohort (treatment-policy).[29][8]

Neither drug is approved. Lilly plans to submit retatrutide for US approval in Q1 2027, and says retatrutide “is an investigational molecule that is legally available only to participants in Lilly’s clinical trials”.[32][30] For the full record, see the retatrutide research profile, retatrutide approval status and the TRIUMPH trial tracker.

Maridebart Cafraglutide vs Tirzepatide

Tirzepatide, also from Lilly, is a single fatty-acid-modified peptide of 4,813.53 Da that activates both the GIP and GLP-1 receptors.[15] It is FDA-approved as Mounjaro (May 2022) and Zepbound (November 2023).[33] MariTide shares the GLP-1 activation but blocks the GIP receptor instead, so the two sit on opposite sides of the GIP paradox.[3]

Feature MariTide Tirzepatide
Developer Amgen Eli Lilly
Molecule Antibody–peptide conjugate, ~153.5 kDa Single peptide, 4,813.53 Da
GLP-1 receptor Activates Activates
GIP receptor Blocks Activates
Interval in trials Every 4 weeks or less often Once weekly
Weight, ITT estimand −12.3% to −16.2% vs −2.5% (Phase 2, 52 wk) −20.9% vs −3.1% (SURMOUNT-1, 15 mg arm, 72 wk)
Weight, efficacy −16.3% to −19.9% vs −2.6% −22.5% vs −2.4%
Stage, Oct 2026 Phase 3 under way; not approved FDA-approved (Mounjaro, Zepbound)

In SURMOUNT-1 (2,539 adults without diabetes, 72 weeks), the 15 mg tirzepatide arm lost 20.9% against 3.1% on placebo (treatment-regimen estimand), or 22.5% against 2.4% on the efficacy estimand.[34] MariTide’s 52-week Phase 2 range was 12.3% to 16.2% against 2.5% (treatment-policy) and 16.3% to 19.9% against 2.6% (efficacy).[8][9] No registered trial compares the two directly, so these are separate trials, not a head-to-head comparison; see the caveats below.[24] For other tirzepatide comparisons, see retatrutide vs tirzepatide, retatrutide vs tirzepatide vs CagriSema and CagriSema vs tirzepatide.

MariTide vs Ozempic and Wegovy (Semaglutide)

Semaglutide, from Novo Nordisk, is a single GLP-1 receptor agonist peptide of 4,113.58 Da.[38] Ozempic and Wegovy are both semaglutide medications: the FDA approved Ozempic for type 2 diabetes in December 2017 and Wegovy as a weight loss medication in June 2021.[37][38][39] Semaglutide selectively activates the GLP-1 receptor.[38] MariTide activates the same receptor while also blocking GIP receptor signalling through its antibody.[3] It also stays in the body longer. In Phase 1, the mean half-life of intact MariTide was about 14 to 16 days, against an elimination half-life of about one week for semaglutide.[3][38]

Feature MariTide Semaglutide
Developer Amgen Novo Nordisk
Molecule Antibody–peptide conjugate, ~153.5 kDa Single peptide, 4,113.58 Da
GLP-1 receptor Activates Activates
GIP receptor Blocks Not targeted
Interval in trials Every 4 weeks or less often Once weekly
Weight, ITT estimand −12.3% to −16.2% vs −2.5% (Phase 2, 52 wk) −14.9% vs −2.4% (STEP 1, 2.4 mg arm, 68 wk)
Stage, Oct 2026 Phase 3 under way; not approved FDA-approved (Ozempic, Wegovy)

In STEP 1 (1,961 adults with obesity or overweight and without diabetes, 68 weeks), the semaglutide 2.4 mg group lost 14.9% of body weight against 2.4% on placebo. Its primary estimand counted results regardless of treatment discontinuation, like Amgen’s treatment-policy estimand.[40] MariTide’s 52-week Phase 2 range on that basis was 12.3% to 16.2% against 2.5%.[8] These are separate trials of different lengths and phases, so the figures are not a head-to-head comparison; see the caveats below.

In STEP 1, nausea and diarrhoea were the most common adverse events with semaglutide, and 4.5% stopped treatment because of gastrointestinal events, against 0.8% on placebo.[40] MariTide side effects in Phase 2 were also mainly gastrointestinal, with nausea, vomiting and constipation the most common.[25]

The two drugs are due to be compared directly in MARITIME-T2D-3, the programme’s only active-comparator trial. It plans to compare MariTide every 4 weeks with weekly semaglutide in about 1,300 adults with type 2 diabetes, with HbA1c at week 68 as the primary end point, and had not started recruiting on October 22, 2026.[36] For the full semaglutide record, see our semaglutide research profile; for other weight loss drugs in development, see the 2026 obesity drug pipeline timeline.

Reading These Comparisons Fairly

The side-by-side figures above are useful for orientation, not for ranking. Seven differences matter:

What the MariTide Data Do Not Show Yet

These gaps are not arguments against the molecule. They are reasons to wait for the MARITIME results before drawing conclusions.

Research Use Notes

Remy Research does not sell MariTide. It is an investigational Amgen medicine in Phase 3, not a research peptide, and this page is a literature and registry review only. It makes no therapeutic, human-use or veterinary claim.

For related reading, see the other incretin profiles in the research library: CagriSema, survodutide, semaglutide and orforglipron (Foundayo). For the classification question, Is retatrutide a peptide or a biologic? explains the 40-amino-acid rule.

Our Research Standards

This profile relies on the WHO INN record, peer-reviewed papers, ClinicalTrials.gov, FDA, DailyMed and European Medicines Agency records, and Amgen and Lilly releases, each checked on October 12, 2026. Where only a company statement or a news report exists, we say so, and every Phase 2 and Phase 3 weight-loss figure carries its estimand label. Trial arms are named only to attribute published results. No therapeutic, human-use, or veterinary-use claim is made here. The October 22, 2026 update re-checked the main ClinicalTrials.gov records and Amgen’s press releases and added the STEP 1 trial and the current semaglutide labels. All references are listed under Sources. Read our editorial policy →

RP
Editorial Review

Editorial Board, Remy Research

The Remy Research Editorial Board reviews Remy's peptide research library, with a focus on analytical verification, clinical-trial interpretation, and compliance-safe scientific communication.

About the editorial team →

Maridebart Cafraglutide Research FAQ

What is maridebart cafraglutide (MariTide)?

Maridebart cafraglutide, also called MariTide and formerly AMG 133, is an investigational obesity drug from Amgen. It is an antibody–peptide conjugate: an antibody that blocks the GIP receptor, carrying two GLP-1 analogue peptides that activate the GLP-1 receptor, designed for treatment once a month or less often.[1][2][4]

Is maridebart cafraglutide (MariTide) a GLP-1?

Partly. It carries two GLP-1 analogue peptides and activates the GLP-1 receptor, but most of the molecule is an antibody that blocks the GIP receptor, so it is not a stand-alone GLP-1 peptide like semaglutide.[4][3]

Is maridebart cafraglutide a peptide?

Only in part. Its antibody part, about 1,328 amino acids, is far above the 40-amino-acid line US regulations use to define a protein; each of the two arms carries a synthetic 29-residue GLP-1 analogue peptide on an 18-residue linker.[2][19]

What is the structure of maridebart cafraglutide?

A human IgG1-kappa antibody against the GIP receptor, made in CHO cells, with two identical GLP-1(7–35) analogues attached through 18-residue glycine–serine-rich linkers by thioether bonds to engineered cysteines. Its average mass is 153,514 Da.[2][17][3]

What are the side effects of maridebart cafraglutide?

Mostly gastrointestinal: nausea, vomiting and constipation were the most common in Phase 2, and gastrointestinal events were less frequent in the arms that used dose escalation and a lower starting dose. Amgen reports that up to 7.8% stopped for gastrointestinal events in those arms, and says it saw no association with bone-density changes.[8][25][9]

Are there maridebart cafraglutide Phase 3 (MARITIME) results?

Not as of October 12, 2026. Amgen calls MARITIME-1 and MARITIME-2 ongoing, and ClinicalTrials.gov shows no posted results and an estimated primary completion of January 2027 for both.[4][6][7]

Is maridebart cafraglutide FDA approved?

No. Drugs@FDA, DailyMed and the European Medicines Agency’s medicines table have no record of it, and Amgen describes it as investigational.[10][11][1]

Maridebart cafraglutide vs tirzepatide: which causes more weight loss?

No trial has compared them directly. The 15 mg tirzepatide arm lost 20.9% at 72 weeks in Phase 3 SURMOUNT-1 (treatment-regimen estimand), while MariTide arms lost 12.3% to 16.2% at 52 weeks in Phase 2 (treatment-policy estimand), so the figures are not directly comparable.[34][8]

Maridebart cafraglutide vs retatrutide: how do they differ?

Retatrutide is a single peptide that activates GIP, GLP-1 and glucagon receptors, while MariTide is an antibody–peptide conjugate that blocks the GIP receptor and activates the GLP-1 receptor. Retatrutide has reported Phase 3 results (in TRIUMPH-1 the 12 mg arm lost 25.0% against 3.9% on placebo at 80 weeks, treatment-regimen estimand) and MariTide has not; neither is approved.[20][3][32]

How does MariTide work?

It works on two hormone pathways at once. Its antibody blocks the GIP receptor, and its two GLP-1 analogue peptides activate the GLP-1 receptor; the Phase 1 paper in Nature Metabolism confirmed both activities in cell-based tests. The case for blocking GIP receptor signalling comes from human genetic studies that linked lower GIP receptor activity to lower body weight.[3][18]

What were the MariTide weight loss results?

In Phase 2, adults with obesity and without diabetes lost 12.3% to 16.2% of body weight at 52 weeks, against 2.5% on placebo (treatment-policy estimand), or 16.3% to 19.9% on the efficacy estimand. Adults with obesity and type 2 diabetes lost 8.4% to 12.3%, against 1.7% on placebo (treatment-policy). No Phase 3 results have been reported.[8][9][36]

What is the MariTide release date?

There is none yet. MariTide is an investigational medicine that is not approved by the FDA or the European Medicines Agency, and Amgen has not announced a regulatory filing. Its two main Phase 3 trials have an estimated primary completion date of January 21, 2027.[10][11][35][36]

What drug class is maridebart cafraglutide?

Its Phase 2 paper calls it a long-acting peptide–antibody conjugate that combines GLP-1 receptor agonism with GIP receptor antagonism, and Amgen calls it an antibody–peptide conjugate. It is not a stand-alone GLP-1 receptor agonist like semaglutide.[8][4][38]

MariTide vs Ozempic: how do they compare?

Ozempic and Wegovy are FDA-approved semaglutide medications. Semaglutide is a single peptide that selectively activates the GLP-1 receptor. MariTide activates the GLP-1 receptor, blocks the GIP receptor and is not approved. In STEP 1, the semaglutide 2.4 mg group lost 14.9% of body weight at 68 weeks against 2.4% on placebo; MariTide’s Phase 2 range was 12.3% to 16.2% at 52 weeks against 2.5%. These are separate trials, not a head-to-head comparison.[38][39][40][8]

Sources

  1. Amgen. The Story of Maridebart Cafraglutide (MariTide): “also known as MariTide, formerly AMG 133… an investigational therapy developed by Amgen”. May 11, 2026. amgen.com ↩
  2. World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN), Proposed INN List 128: maridebart cafraglutide (IgG1-kappa anti-GIPR human monoclonal antibody, produced in CHO cells, conjugated with two identical GLP-1 analogues via a fused 18-mer linker). WHO Drug Information 2022;36(4). cdn.who.int ↩
  3. Véniant MM, Lu SC, Atangan L, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024;6(2):290-303. doi: 10.1038/s42255-023-00966-w · PMID: 38316982 ↩
  4. Amgen. Amgen Reports Second Quarter 2026 Financial Results (MariTide programme update: MARITIME-1 and MARITIME-2 “ongoing”; MARITIME-CV, -HF, -OSA-1, -OSA-2, -SWITCH and both extensions enrolling; three Phase 3 studies in type 2 diabetes to start in 2026). August 4, 2026; checked October 12, 2026. amgen.com ↩
  5. Amgen. Investor news releases, 2026 (newest release dated September 22, 2026; no MariTide or MARITIME results release in 2026). Checked October 12, 2026. investors.amgen.com ↩
  6. ClinicalTrials.gov. NCT06858839 (MARITIME-1): maridebart cafraglutide in adults without type 2 diabetes who have obesity or are overweight. Phase 3; 3,853 enrolled; active, not recruiting; estimated primary completion January 21, 2027; no results posted. Checked October 12, 2026. clinicaltrials.gov/study/NCT06858839 ↩
  7. ClinicalTrials.gov. NCT06858878 (MARITIME-2): maridebart cafraglutide in adults with type 2 diabetes who have obesity or are overweight. Phase 3; 1,105 enrolled; active, not recruiting; estimated primary completion January 21, 2027; no results posted. Checked October 12, 2026. clinicaltrials.gov/study/NCT06858878 ↩
  8. Jastreboff AM, Ryan DH, Bays HE, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. N Engl J Med. 2025;393(9):843-857. doi: 10.1056/NEJMoa2504214 · PMID: 40549887 ↩
  9. Amgen. Results from Amgen’s Phase 2 obesity study of monthly MariTide presented at the American Diabetes Association 85th Scientific Sessions (treatment-policy and efficacy estimand results; discontinuation for gastrointestinal adverse events; Part 2 design; Phase 1 lower-start study). June 23, 2025. amgen.com ↩
  10. U.S. Food and Drug Administration and U.S. National Library of Medicine. Drugs@FDA and drug-label records (openFDA) and DailyMed searched for maridebart and MariTide, October 12, 2026: no approval or label (openFDA data updated October 9, 2026; DailyMed database published October 9, 2026). dailymed.nlm.nih.gov ↩
  11. European Medicines Agency. Medicines data table (export generated October 12, 2026): no entry for maridebart cafraglutide or MariTide. ema.europa.eu ↩
  12. World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN), Recommended INN List 90: maridebart cafraglutide. WHO Drug Information 2023;37(3). cdn.who.int ↩
  13. World Health Organization. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2018 (stem “-glutide”: glucagon-like peptide analogues). cdn.who.int ↩
  14. Guimaraes Koch SS, Thorpe R, Kawasaki N, et al. International nonproprietary names for monoclonal antibodies: an evolving nomenclature system. MAbs. 2022;14(1):2075078. doi: 10.1080/19420862.2022.2075078 · PMID: 35584276 ↩
  15. U.S. National Library of Medicine, DailyMed. ZEPBOUND (tirzepatide) prescribing information, section 11: “a GIP receptor and GLP-1 receptor agonist”; molecular weight 4813.53 Da. Checked October 12, 2026. dailymed.nlm.nih.gov ↩
  16. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi: 10.1016/j.cmet.2022.07.013 · PMID: 35985340 ↩
  17. Wu B, Falsey JR, Netirojjanakul C, et al. Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity. J Med Chem. 2026;69(8):9348-9362. doi: 10.1021/acs.jmedchem.6c00032 · PMID: 41941715 ↩
  18. Amgen. Decoding the Genetics of Obesity (MariTide described as an antibody-peptide conjugate; more than 150 conjugate variations tested; deCODE GIPR variant findings). September 3, 2025. amgen.com ↩
  19. Electronic Code of Federal Regulations. 21 CFR 600.3(h)(6): a protein is “any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size”. Checked October 12, 2026. ecfr.gov ↩
  20. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published online September 29, 2026. doi: 10.1056/NEJMoa2604169 · PMID: 42814954 ↩
  21. Killion EA, Wang J, Yie J, et al. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci Transl Med. 2018;10(472):eaat3392. doi: 10.1126/scitranslmed.aat3392 · PMID: 30567927 ↩
  22. Killion EA, Chen M, Falsey JR, et al. Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism. Nat Commun. 2020;11(1):4981. doi: 10.1038/s41467-020-18751-8 · PMID: 33020469 ↩
  23. Amgen. Amgen Reports Fourth Quarter and Full Year 2025 Financial Results (Phase 2 Part 2 complete and the Phase 2 type 2 diabetes study described in words only). February 3, 2026. amgen.com ↩
  24. ClinicalTrials.gov. Registry search for maridebart, AMG 133 or MariTide: 30 studies, all sponsored by Amgen (12 Phase 3, 3 Phase 2, 15 Phase 1); results posted for two Phase 1 studies only. Searched October 20, 2026. clinicaltrials.gov ↩
  25. Amgen. Amgen announces robust weight loss with MariTide in people living with obesity or overweight at 52 weeks in a Phase 2 study (most common adverse events; discontinuation rates; bone mineral density statement; MARITIME Phase 3 programme announced). November 26, 2024. amgen.com ↩
  26. Cox CE. Weight-Loss Drug MariTide Gains Momentum in Phase II Trial. TCTMD, June 25, 2025 (secondary news report of the Phase 2 presentation). tctmd.com ↩
  27. Amgen. Amgen provides statement on MariTide Phase 1 data (no association seen between MariTide and bone mineral density changes). November 13, 2024. amgen.com ↩
  28. Yie J, Mou Z, Liu X. Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications. Antib Ther. 2026;9(3):367-380. doi: 10.1093/abt/tbag029 · PMID: 42592044 ↩
  29. Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. doi: 10.1016/S0140-6736(26)01861-1 · PMID: 42810372 ↩
  30. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline, efficacy estimand; “legally available only to participants in Lilly’s clinical trials”). May 21, 2026. investor.lilly.com ↩
  31. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi: 10.1056/NEJMoa2301972 · PMID: 37366315 ↩
  32. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (BLA submission to FDA planned for Q1 2027). July 23, 2026. investor.lilly.com ↩
  33. U.S. Food and Drug Administration. Drugs@FDA (openFDA): tirzepatide, NDA 215866 Mounjaro (original approval May 13, 2022) and NDA 217806 Zepbound (original approval November 8, 2023). Checked October 12, 2026. api.fda.gov ↩
  34. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi: 10.1056/NEJMoa2206038 · PMID: 35658024 ↩
  35. Amgen. Press releases (newest dated October 20, 2026; no MariTide Phase 3 results or regulatory filing release). Checked October 22, 2026. amgen.com ↩
  36. ClinicalTrials.gov. Records re-checked October 22, 2026: NCT06858839 (MARITIME-1) and NCT06858878 (MARITIME-2), active, not recruiting, estimated primary completion January 21, 2027, no results posted; NCT07225686 and NCT07226765 (MARITIME-OSA-1 and -OSA-2, obstructive sleep apnea, apnea–hypopnea index at week 52); NCT07037459 (MARITIME-HF, cardiovascular death or heart failure events) and NCT07037433 (MARITIME-CV, major adverse cardiovascular events), each up to about 35 months; NCT07866066 (MARITIME-T2D-3, open-label, maridebart cafraglutide every 4 weeks vs semaglutide once weekly, about 1,300 participants with type 2 diabetes, HbA1c at week 68, not yet recruiting). clinicaltrials.gov ↩
  37. U.S. National Library of Medicine, DailyMed. OZEMPIC (semaglutide) prescribing information, sections 1 and 12.1: indicated for adults with type 2 diabetes; semaglutide “stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner”. Checked October 22, 2026. dailymed.nlm.nih.gov ↩
  38. U.S. National Library of Medicine, DailyMed. WEGOVY (semaglutide) prescribing information, sections 11, 12.1 and 12.3: molecular weight 4113.58 g/mol; semaglutide “selectively binds to and activates the GLP-1 receptor”; “GLP-1 is a physiological regulator of appetite and caloric intake”; elimination half-life of approximately 1 week. Checked October 22, 2026. dailymed.nlm.nih.gov ↩
  39. U.S. Food and Drug Administration. Drugs@FDA (openFDA): semaglutide, NDA 209637 Ozempic (original approval December 5, 2017) and NDA 215256 Wegovy (original approval June 4, 2021). Checked October 22, 2026. api.fda.gov ↩
  40. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi: 10.1056/NEJMoa2032183 · PMID: 33567185 ↩

For the wider pipeline, continue to the 2026 obesity drug approval tracker and the research library. For editorial standards, see the research standards page.